{"id":"eu-approved-humira","safety":{"commonSideEffects":[{"rate":"7–26","effect":"Injection site reactions"},{"rate":"7–17","effect":"Upper respiratory tract infections"},{"rate":"12","effect":"Headache"},{"rate":"1–3","effect":"Serious infections (including tuberculosis)"},{"rate":null,"effect":"Malignancy risk"},{"rate":null,"effect":"Demyelinating disease"}]},"_chembl":{"chemblId":"CHEMBL5857501","moleculeType":null,"molecularWeight":"542.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Humira (adalimumab) binds directly to soluble and membrane-bound TNF-alpha, preventing its interaction with TNF receptors on immune cells and reducing the inflammatory cascade. This suppresses the production of pro-inflammatory cytokines and chemokines, thereby reducing inflammation and immune-mediated tissue damage across multiple organ systems.","oneSentence":"Humira is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha, a key inflammatory cytokine driving autoimmune and inflammatory diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:47.194Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Hidradenitis suppurativa"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT05495568","phase":"PHASE3","title":"To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2022-11-07","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":367},{"nctId":"NCT03849313","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-03-20","conditions":"Healthy Volunteers","enrollment":390},{"nctId":"NCT03970824","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-05-31","conditions":"Healthy","enrollment":312},{"nctId":"NCT03014947","phase":"PHASE1","title":"MSB11022 in Healthy Subjects","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2014-05","conditions":"Healthy Subjects","enrollment":237},{"nctId":"NCT03579823","phase":"PHASE1","title":"Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2018-05-21","conditions":"Healthy Volunteers","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"EU-approved Humira","genericName":"EU-approved Humira","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"Humira is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha, a key inflammatory cytokine driving autoimmune and inflammatory diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}